+34 620 10 75 37info@nanbiosis.com

Posts Taged oitb

You are here : Home / Posts Tagged "OITB"

NANBIOSIS sesion in the CIBER-BBN and CIBEREHD annual meeting. SAFE-N-MEDTECH Project: Outcomes and Future Prospects.

The annual conference of the scientific áreas of CIBER (the most important Centre for Biomedical Research in Spain) are hotly awaited every year for the CIBER community as a foro to be updated about emerging key technologies and discuss about research lines and results, find new opportunities to collaborate and join efforts towards common objectives.

Moreover, this year, the Annual Conference of CIBER-BBN (Bioengineering, Biomaterials and Nanomedicine) has been organized as a collective event scheme together with the scientific area of CIBEREHD (Digestive and Liver Diseases). Both areas have already shared experiences of collaborative projects, demonstrating the complementarity of their fields. The results of these seed projects were presented on the firs working day, and a new edition of seed collaborative projects between the two areas was announced.

NANBIOSIS session took place in the afternoon of the second day. It was dedicated to SAFE-N-MEDTECH Project: Outcomes and Future Prospects.

SAFE-N-MEDTECH is a H2020 project (GA: 814607) funded by the European Commission under the topic DT-NMBP-02-2018-OITB for Safety Testing of Medical Technologies for Health (IA). The Open Innovation Test Bed (OITB) is an initiative launched by the European Commission with the aim of accelerating the development of medical devices based on nanotechnologies in Europe and abroad.

The project, ended this september, counted with 28 partners with a total funding of 15 million euros. The Consorcio Centro de Investigación Biomédica en Red (CIBER) is partner of the project through the Spanish Research Infrastructure NANBIOSIS -ICTS integrated by CIBER, CCMIJU and Ibima -Platafprma BIONAND, several units of the ICTS NANBIOSIS carried out some of the F/Q, in vitro and in vivo characterizations applied to the Pilot Test Cases described in the project.

Ángel del Pozo, from Biokeralty Research Institute AIE, coordinator of the project, explained the development of the project with its outcomes and its future prospects.

M. Luisa González, from UEx and Scientific Director of U16 of NANBIOSIS, explained the joint with CCMIJU on the Stryker case materials, testing bacterial colonization. This joint experience in the project has been organized as a new cutting-edge biomedical solution that NANBIOSIS ofer to its clients.

Montserrat Rodríguez-Núñez, from NANBIOSIS U2 Custom Antibody Service (CAbS) at IQAC-CSIC talked about the participation of the unit in the project by Assessment of affinity parameters for immunosensor development.

It also took place the annual meetting of the NANBIOSIS Scientific Advisory Committee to deliberate the key actions of the ICTS and.

Related news:

2023 Annual Conference of CIBER-BBN and NANBIOSIS with CIBEREHD
2023 Annual Conference of CIBER-BBN and NANBIOSIS

• Read More

Safe-n-MedTech celebrates its 48th Month Management Committee Meeting

The event brought together high-level experts from 3 continents in the field of nanotechnology.

Barcelona, March 27th, 2023

The EU funded project Safe-n-MedTech celebrated its official 48th Month Management Committee Meeting on March 7th to 9th 2023 with a private event taking place in Lisbon. The event was organized and hosted by Instituto Medicina Molecular João Lobo Antunes (IMM), who are partners in this project.

The Consortium had the pleasure to count with the virtual attendance of the Project Adviser, Ozlem Cangar (HADEA), who could follow the critical aspects of the project progress.

The meeting was opened by Ángel del Pozo, Deputy Manager of Programs Strategy at Biokeralty Research Institute, and Scientific and Technical Manager of the project, who offered a comprehensive overview of the latest developments concerning each of the work packages.

Following this, work package leaders and representatives from all partners presented the most significant advances in their current tasks, and highlighted the results obtained to date in each of the project’s work packages. They also had the opportunity to share the latest progress within the Test Cases that are being carried out. On the second day, the consortium established the critical tasks and timelines to fulfill for the successful completion of the project.

Prior to the main event, a business meeting was held at the facilities of IMM with the aim to discuss the next steps for the successful development of the OITB Pathway, a non-profit organization derived from this project, which will act as a single-entry point (SEP) to help technologies in health care into the market.

With less than 7 months ahead towards the end of the project it is expected that work will continue in a collaborative and committed manner to achieve the established objectives and goals. At this stage, partners are strongly focused on public relations and communication activities. Dissemination of project results is essential for long-term success.

The two and a half-day event offered all partners the opportunity to discuss about all the ongoing activities, next challenges and the best way to face them. “The project ends in 7 months, but we will continue building OITB Pathway and delivering all our services and knowledge. We have set the path with clear plans towards the future!”, Ángel del Pozo pointed.

About Safe-n-MedTech
The EU funded Safe-n-MedTech is a 4-year project that is working on an open access, innovative platform to provide the knowledge, networks and services needed for the development of nanotechnology-based medical and diagnostic devices. The objective is to offer the service to leading companies and laboratories.

For more information visit: www.safenmt.com

• Read More

SAFE-NMT Open Call for development and market of innovative MedTech solutions based on nanotechnology

An Open Call within H2020 project SAFE-N-MEDTECH OITB  -Safety testing in the life cycle of nanotechnology-enabled medical technologies for health– has been launched with the objective of providing services and support to companies and other organizations with the aim of accelerating the development and commercialization of innovative MedTech solutions based on nano-enabled technology.

SAFE-N-MEDTECH  in which CIBER-BBN is a partner througth its ICTS NANBIOSIS, gathers expertise from 28 partners around the world focused in enabling the safe translation of nano-enabled medical technologies from Proof of Concept to markets and clinical practice funded project

SAFE-N-MEDTECH with its key expertise and extensive knowledge in nano-enabled medical technologies, offers characterization, pre-clinical validation, access to biobanks and patient samples, scale up and regulatory support, technology assessment and horizon scanning.

Submission deadline: March 21st 2022, 23:59 CET

CALL DOCUMENTS – HOW TO APPLY:

  • Guidelines for Applicants The Guide for Applicants contains the basic information needed to guide you in preparing a proposalfor submission to the SAFE-N-MEDTECH Open Call. It gives an introduction on how to structureyour proposal. It also describes how to submit the proposal and the evaluation criteria.
  • Application Form

EXAMPLES OF SUPPORT SERVICES:

Nanoparticle Characterisation

  • Chemical Composition
  • Physical properties
  • Drug loading/release
  • RNA quantification and integrity
  • Sterility and Toxicity

Pre-Clinical Development

  • Antibody production
  • Peptide/Protein synthesis
  • Oligonucleotide synthesis
  • Immune response monitoring
  • Cellular assays
  • Biological evaluation
  • Nanoparticle development
  • Design and optimisation of biosensor platforms
  • Access to human samples and Biobanks
  • In vivo experiments

In Silico

  • In silico modelling

Clinical Validation

  • RNA extraction
  • RNA/DNA sequencing
  • Binding affinity measurement
  • Immune response monitoring

Assistance in prototyping and qualification of manufacturing facilities

Business development coaching, links with business angels, investors, capital risk, etc

Regulatory Assessment

  • Regulatory support to Europe and US approval

Health Technology Assessment

  • First evaluation of the project/product based on Health Technology Assessment (HTA)and Healthcare system needs
  • Technology scanning to identify redundancies/synergies

This call uses funds obtained within the scope of the SAFE-N-MEDTECH project funded by European Union´s Horizon 2020 Research and Innovation Program. (Grant Agreement No. 814607)

• Read More

OITBs OPEN CALL TO FIGHT COVID19 – SafeNMT OITB project

JOINT OITBS OPEN CALL TO FIGHT COVID 19

SAFE-N-MEDTECH OITB project in which CIBER-BBN is a partner througth its ICTS NANBIOSIS, gathers expertise from 28 partners around the World focused in enabling the safe translation of nano-enabled medical technologies from Proof of Concept to markets and clinical practice. The sudden COVID-19 outbreak has meant an unforeseen challenge that requires rapid answers from the Science, Technology and Innovation Community. These is a framework where SafeNMT could deploy all its potential: first, because nanotechnology is a Key Enabling Technology that can contribute to innovative approaches to fight COVID 19 and/or other viral pandemics. Second, because the integration of capabilities in SafeNMT should be a key driver to integrate, accelerate and translate nanotechnology innovations from TRLs 4-5 to TRLs 6-7.

In this context, and in the frame of the Joint OITBs Open Call to fight COVID 19, we aim in opening our services, at no cost, for selected proposals which accomplish the following conditions:

  • Innovations for prevention, diagnostic and/or therapy for COVID 19 based on the use of nanotechnology applied to Medical Devices and In Vitro Diagnostic
  • The expressions of interest should present a solid S&T background and a sufficient technological maturity (starting TRLs 4-5)
  • A clear development pathway, with an initial identification of product needs is encouraged

What we offer (non-exhaustive list, to be agreed with the selected expressions of interest – Consult the services in our catalogue):

  • First evaluation of the project/product based on Health Technology Assessment (HTA) and Healthcare system needs provided by our pool of experts
  • Technology scanning to identify redundancies/synergies
  • Nanomaterial characterization
  • In vitro preclinical research
  • Access to clinical samples and Biobanks
  • Assistance in prototyping and qualification of manufacturing facilities
  • Regulatory advice and support in the adapted European regulation for COVID 19 medical technologies
  • Links to clinical networks
  • Business development coaching, links with business angels, investors, capital risk, etc.

Typically, the project will cover costs related to activities mentioned above, according to the budget limits available. If outstanding expenses beyond the available budget are needed, these will need to be covered by the user. The project won’t be able to cover formal regulatory costs, production costs, clinical development costs or any external costs that might be needed for the testing and production of the nano-enabled Medical Technology/ies.
Please note that all information provided will be treated confidential and is stored only for the purpose of this call.

Submission deadline: October 2nd, 2020, 5:00 p.m. CET.

Applicants will be informed about the outcome of their application in mid October. Activities are envisaged to start beginning of November.
APPLY HERE!

• Read More

Safe-N-Medtech kicks off in Bilbao

The Safe-N-MedTech European Project kcks off in Bibao to create an open innovation platform that accelerates the development of medical devices based on nanotechnologies.

During 2 and 3 of May took place in Bilbao, at the University of the Basque Country, the kick off meeting of the European project Safe-N-Medtech organized by Osteba, the HTA Unit of the Ministry of Health of the Basque Country (Spain) in collaboration with BIOPRAXIS-BIOKERALTY.

Safe-N-Medtech, counts with 28 partnerts coordinated by TECNAN (Navarran company with great experience in Nano products), together with BIOPRAXIS-BIOKERALTY, the research branch of the global health companies Keralty and Praxis. The new project is part of the Open Innovation Test Bed initiative (OITB) launched by the European Commission with the aim of accelerating the development of medical devices based on nanotechnologies in Europe and abroad. The project has a European funding of 15 million euros.

CIBER-BBN participates as a partner in the Safe-N-Medtech throught its Scientific Infraestructure, the ICTS NANBIOSIS. Several units of NANBIOSIS from CIBER-BBN and JUMISC wiil carry out some of the F/Q, in vivo and in vitro characterizations applied to pilot test cases, NANBIOSIS is the leader of WP3 Preclinical Research in nano-enabled MTs.

Society and clinical practice raise a growing demand for new biomaterials, ICTs, medical devices and in vitro diagnostics (Medical Technologies-MTs) based on micro and nanotechnologies. In addition to the challenge of time, new technologies are subject to other pressing factors, such as qualification, regulation, cost, biocompatibility and the need to be applicable throughout the world. Medical devices based on nanotechnologies can be applied in almost all medical areas, with an important presence in areas such as cancer, regenerative medicine, advanced therapies, neurology, cardiology, orthopedics and dentistry.

The initiative aims to build an open innovation platform to offer companies and reference laboratories the capabilities, knowledge, networks and services necessary for the development, testing, evaluation, improvement and exploitation of the market of medical devices and diagnostic based in nanotechnology. This platform will offer a multidisciplinary and market-oriented innovation approach for SMEs, health care providers and industries, accelerating the transfer to the market of these new medical devices. During the first years of project work, the partners will develop their services and test them in different case studies, so that, Safe-N-Medtech OITB can become a sustainable and competitive services platform for companies to accelerate their developments according to the necessary regulatory requirements and ensure the safety and effectiveness of their medical devices based on nanotechnologies.

• Read More